Mass psychogenic response to human papillomavirus vaccination

Jim P Buttery, Simon Madin, Nigel W Crawford, Sonja Elia, Sophie La Vincente, Sarah Hanieh, Lindsay Smith and Bruce Bolam
Med J Aust 2008; 189 (5): . || doi: 10.5694/j.1326-5377.2008.tb02018.x
Published online: 1 September 2008

Cervical cancer associated with human papillomavirus (HPV) affects approximately 1000 Australian women each year, causing about 300 deaths.1 The newly licensed HPV vaccines Gardasil (CSL Limited), a quadrivalent vaccine (4vHPV), and Cervarix (GlaxoSmithKline Vaccines), a bivalent vaccine (2vHPV), induce protection against the two most common strains of HPV, which cause 70% of all cervical cancers.2,3

  • Jim P Buttery1,2,3
  • Simon Madin4
  • Nigel W Crawford1,2,3
  • Sonja Elia1,3,5
  • Sophie La Vincente1,5
  • Sarah Hanieh2,3
  • Lindsay Smith6
  • Bruce Bolam4

  • 1 SAEFVIC, Murdoch Childrens Research Institute, Royal Children’s Hospital, Melbourne, VIC.
  • 2 Department of Paediatrics, University of Melbourne, Melbourne, VIC.
  • 3 Infectious Diseases Unit and Immunisation Service, Department of General Medicine, Royal Children’s Hospital, Melbourne, VIC.
  • 4 Victorian Department of Human Services, Melbourne, VIC.
  • 5 National Centre for Epidemiology and Population Health, Australian National University, Canberra, ACT.
  • 6 Department of Paediatric Neurology, Monash Medical Centre, Melbourne, VIC.


Competing interests:

GlaxoSmithKline supported Jim Buttery’s travel to speak at an international meeting by payment to the Murdoch Childrens Research Institute.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.